Royalty Pharma Sub-Manager, LLC — Q1 2026 13F-HR

← Royalty Pharma Sub-Manager, LLC

Q1 2026 · 13F-HR

Royalty Pharma Sub-Manager, LLCholdings as filed

Filed 2026-05-14 · accession 0002081668-26-000006

$172.8M

Reported value

Positions

2026-03-31

Period end

View analyzed profile →PRO

The Brief · Royalty Pharma Sub-Manager, LLC · Q1 2026

AI · grounded in 13F

Royalty Pharma Sub-Manager, LLC increased its position in Zenas Biopharma, Inc. BCAX by 89.06%. The fund added one new position to its portfolio. Total assets under management stood at $172,764,205 across four positions.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
23282W605	CYTK	CYTOKINETICS, INC	$64.6M	37.4%	980,392	Common	SOLE
055477103	BCAX	ZENAS BIOPHARMA, INC.	$46.7M	27.0%	2,388,150	Common	SOLE
09058V103	BCRX	BIOCRYST PHARMACEUTICALS INC	$36.6M	21.2%	3,846,154	Common	SOLE
G1110E107	BHVN	BIOHAVEN LTD	$24.8M	14.4%	2,936,507	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.